Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Vascepa Data Should Make Amarin Longs Worried
Quoth the Raven • AMRN • Mon, May 20, 12:55 ET
Amarin: It's The Strategy, Not The Science
EnhydrisPECorp • AMRN • Mon, May 20, 09:07 ET
A Broad Look At Teva's Pipeline
StockRiters • TEVA • Mon, May 20, 07:46 ET
Alexza Pharmaceuticals Has A Partner In Big Pharma, Now What?
Bio Matt • TEVA, ALXA • Wed, May 15, 08:29 ET
Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaning
Avi Greenberg • GALE, TEVA, ALXA • Wed, May 15, 05:17 ET
Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day
PropThink • OPTR, HSP, TEVA • Tue, May 14, 10:23 ET
Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground
Brian L. Wilson • AMRN • Mon, May 13, 18:33 ET
Teva: An Ideal Long-Term Pharma Stock
Emerging Equities • TEVA • Mon, May 13, 10:42 ET
This Stock Deserved Its Sudden Upswing
Northwest Trader • VRTX • Mon, May 13, 02:31 ET
Income Idea: 2 Undervalued Drug Makers With Rising Gross Profit Margins
Kapitall • SCLN, WCRX • Fri, May 10, 06:42 ET
Risky Amarin Sets Its Cash Pile On Fire
Quoth the Raven • AMRN • Thu, May 9, 20:23 ET
Isis Pharmaceuticals Slides A Little Despite Strong Earnings
StockBaller • ISIS • Thu, May 9, 14:36 ET
Review Of Depomed's First Quarter 2013 Results
Jason Napodano • MRK, JNJ, SNTS • Thu, May 9, 11:48 ET
Sucampo's Stock Could Reach $12, Says Maxim's Senior Vice President
Ben Yoffe • SCMP • Thu, May 9, 10:38 ET
Vertex Debt Conversion Is Not Bad For Shareholders
Northwest Trader • VRTX • Thu, May 9, 03:25 ET
Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
PropThink • AZN, POZN • Wed, May 8, 14:30 ET
Teva's CEO Thinks China Is A 'Natural Fit'
ChinaBio Today • TEVA • Wed, May 8, 02:02 ET
Allergan: Is It Still Overvalued?
Derastone • AGN • Mon, May 6, 15:27 ET
Can Amarin Make Me A Believer This Thursday?
Quoth the Raven • AMRN • Mon, May 6, 12:59 ET
Durect: Pfizer Hints At Progress With Remoxy
PropThink • PFE, DRRX • Fri, May 3, 10:47 ET
Ampio Pharma Initiates Phase III, Investors Extend Momentum
Brian L. Wilson • SNY, AMPE • Fri, May 3, 09:39 ET
Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares
Edward Vranic • VRTX • Fri, May 3, 07:54 ET
Why Did Pain Therapeutics Increase Over 25%?
C.R. Jackson • ACUR, DRRX, PFE • Thu, May 2, 01:15 ET
Amarin: The Bull Argument (Or How I Learned To Stop Worrying And Love Vascepa)
Bond Wells • AMRN • Tue, Apr 30, 18:04 ET
Amarin's Performance Issues: Here To Stay?
Dallas Salazar • AMRN • Mon, Apr 29, 13:30 ET
Teva Pharmaceuticals Is A Bitter Pill To Swallow
Ron Sommer • TEVA • Sun, Apr 28, 19:47 ET
Muscle Pharm Will 'Bulk Up' Your Returns
Buffett Junior • DKS, GNC, VSI • Thu, Apr 25, 06:03 ET
Vertex Spikes On Phase II Data, Then The CFO Sells His Shares
Edward Vranic • VRTX • Wed, Apr 24, 01:50 ET
An Undervalued Pharmaceutical Company With Remarkable Results
Steffen Jørgensen • TEVA • Tue, Apr 23, 17:35 ET
Why I'm Adding To My Amarin Short Position
Quoth the Raven • AMRN • Mon, Apr 22, 14:31 ET
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • ALKS, AMGN, AMRI • Sat, Apr 20, 09:33 ET
By Adding Cost Effective Suppliers, Amarin Looks To Gain Market Share With Vascepa
Heather Ingrassia • AMRN • Thu, Apr 18, 11:31 ET
FDA Bars Old OxyContin Generics: Read-Through To Continue Boosting Endo
PropThink • IPXL, ENDP • Wed, Apr 17, 12:08 ET
No NCE Decison For Amarin's Vascepa: The Launch Trudges Along
Brian L. Wilson • GSK, AMRN • Tue, Apr 16, 08:54 ET
Why Are Investors So Excited About Chimerix's Technology?
C.R. Jackson • CMRX • Mon, Apr 15, 12:11 ET
NovaBay: Working On An Effective Treatment For Viral Conjunctivitis
David Sobek • NBY • Sat, Apr 13, 08:39 ET
Isis Pharmaceuticals - Antisense Making Sense
Jane Edmondson • ISIS • Fri, Apr 12, 15:40 ET
Biodel: Reemerging From Obscurity In 2013
Chemistfrog • LLY, BIOD • Thu, Apr 11, 00:29 ET
Can Teva's Short-Term Pressure Be Justified?
Nick Chiu • BIIB, MYL, NVS • Fri, Apr 5, 15:05 ET
Telik: A Possible Investment, But Only After Much Consideration
Chemistfrog • TELK • Fri, Apr 5, 01:32 ET
Strength In Sucampo Heading Into FDA Decision And Analyst Activity
Brian L. Wilson • SCMP • Thu, Apr 4, 13:53 ET
Astex Pharmaceuticals: A Catalyst-Driven Year Ahead
PropThink • CELG, ASTX • Thu, Apr 4, 12:28 ET
Preserving Its Strategic Partnerships Will Be A Key Catalyst For Isis Pharmaceuticals In 2013
Heather Ingrassia • AZN, BIIB, ISIS • Thu, Apr 4, 03:02 ET
Endo Health's New Exec Expected To Swing Right Into Action
PropThink • ENDP • Wed, Apr 3, 08:02 ET
Apricus Biosciences: A Transformative Year Ahead
Chemistfrog • ABT, NVS, PFE • Mon, Apr 1, 15:43 ET
The Original Marijuana Stock Files For U.S. IPO
TheScottMarket • CBIS.OB, HEMP.PK, MDBX.PK • Mon, Apr 1, 14:50 ET
Novo Nordisk: Buy This 10 Year 27.47% CAGR Stock After Its Recent 16.94% Pullback
Nicholas Ward • NVO • Mon, Apr 1, 09:12 ET
Endo Health's New CEO To Reveal Strategy: Good News For Investors?
OneMedPlace • VRX, ENDP • Sun, Mar 31, 03:42 ET
MusclePharm, An American Success Story
Dutch Trader • GNC, VSI, WAG • Thu, Mar 28, 14:10 ET
Endo Health's New CEO Will Be Revealing His Strategy - Good News For Investors?
PropThink • JNJ, VRX, ENDP • Thu, Mar 28, 11:19 ET

First Page
Previous Page
1 - 50 of 1186
Next Page
Last Page